Vector Biopharma AG has secured a $30 million series A funding commitment from founding investor Versant Ventures to take forward a new gene delivery platform developed by Andreas Plückthun, of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback